{
    "nctId": "NCT00225758",
    "briefTitle": "Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy",
    "officialTitle": "Lapatinib in Endocrine-Resistant Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 27,
    "primaryOutcomeMeasure": "Determine the Response Rate and Progression Free Survival of Hormone Therapy-resistant Patients With Metastatic Breast Cancer Treated With the Same Continued Hormonal Agent With the Addition of Lapatinib.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histologically or cytologically proven metastatic breast cancer.\n* Patients with either estrogen or progesterone receptor positivity on the most recently examined tumor biopsy.\n* Patients must have most recently been using an anti-estrogen (tamoxifen, toremifene, raloxifene, or fulvestrant) or an aromatase inhibitor.\n* Patients must have had either a partial response or better, or stable disease for 24 weeks or longer, followed by disease progression, on the current or most recent hormonal therapy for management of metastatic breast cancer.\n* Patients must be enrolled within six weeks of defining disease progression on hormonal therapy.\n* Patients must have stopped fulvestrant at least four weeks prior and other endocrine therapy at least two weeks prior to enrollment on study.\n* Patients must have either measurable disease or at least one evaluable bone lesion that has not been irradiated. Measurable disease is not necessary.\n* Estimated life expectancy of at least 6 months.\n* ECOG performance status 0-2.\n* Adequate hematologic, hepatic, and renal function.\n* Patients must be post-menopausal, or they must be practicing either abstinence or an adequate method of contraception, or their sexual partner must be sterile.\n* All patients must be able to swallow, retain, and absorb oral medications.\n* All patients must be able to give informed consent indicating that they are aware of the investigational nature of this study.\n\nExclusion Criteria:\n\n* Patients may not have received an investigational agent within the prior four weeks.\n* Patients may not have received trastuzumab within three weeks of study entry.\n* Patients may not have had major surgery within the prior two weeks.\n* Patients may not have Class III or IV heart failure as defined by the NYHA functional classification system.\n* Patients may not have a left ventricular ejection fraction \\< 40% based on MUGA or echocardiogram.\n* Patients may not have uncontrolled brain metastases or leptomeningeal disease.\n* Patients may not have rapidly progressive visceral metastases.\n* Patients may not have a serious illness or conditions including clinically significant cardiac disease, angina pectoris, serious psychiatric disorder, or an active infection.\n* Patients may not be receiving concurrent medications (listed in the protocol) which may interact with lapatinib during treatment with lapatinib.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}